贝利尤单抗在改良DORIS缓解和无激素LLDAS达标上优于安慰剂:五项III期SLE试验的事后分析
该事后分析 pooled 五项III期SLE试验,比较贝利尤单抗与安慰剂在排除糖皮质激素成分的改良DORIS缓解(non-GC-DORIS)和改良LLDAS(non-GC-LLDAS)达标率。第52周贝利尤单抗组non-GC-DORIS达标率18% vs 安慰剂13%(RR 1.44, 95%CI 1.20-1.71, p<0.001),non-GC-LLDAS达标率32% vs 21%(RR 1.50, 95%CI 1.32-1.71, p<0.001)。结论认为贝利尤单抗与更高的排除GC成分的DORIS缓解和LLDAS达标相关。
要点
- 贝利尤单抗组第52周non-GC-DORIS达标率18%,安慰剂组13%,RR 1.44(95%CI 1.20-1.71),p<0.001。
- 贝利尤单抗组第52周non-GC-LLDAS达标率32%,安慰剂组21%,RR 1.50(95%CI 1.32-1.71),p<0.001。
- 多数亚组结果一致,高疾病活动度亚组差异通常更大,亚洲和白人亚组贝利尤单抗显著更高。
核心结论
- 贝利尤单抗相比安慰剂与更高的排除糖皮质激素成分的DORIS缓解和LLDAS达标率相关。
研究设计与样本
- 事后分析 pooled 五项III期SLE临床试验(BLISS-76、BLISS-52、North East Asia、BLISS-SC、EMBRACE)的成人SLE患者数据。
- 贝利尤单抗给药方式为10 mg/kg每月静脉或200 mg每周皮下,联合标准治疗,对照为安慰剂联合标准治疗。
- 分析比较至第52周总体人群及特定亚组的non-GC-DORIS和non-GC-LLDAS达标率,后者仅基于SLE疾病活动指数2000和医生整体评估计算。
主要发现
- 第52周non-GC-DORIS达标率贝利尤单抗组(n=1869)18% vs 安慰剂组(n=1217)13%,RR 1.44(95%CI 1.20-1.71),p<0.001。
- 第52周non-GC-LLDAS达标率贝利尤单抗组32% vs 安慰剂组21%,RR 1.50(95%CI 1.32-1.71),p<0.001。
- 多数分析亚组结果相似,高疾病活动度亚组差异通常大于低疾病活动度亚组,亚洲和白人亚组贝利尤单抗达标率显著高于安慰剂。
- 排除GC成分的达标率约为既往使用完整定义报告的两倍。
关键数值与推荐
- non-GC-DORIS和non-GC-LLDAS定义排除糖皮质激素成分,仅基于SLE疾病活动指数2000和医生整体评估计算。
- 第52周non-GC-DORIS达标率贝利尤单抗18% vs 安慰剂13%,RR 1.44(95%CI 1.20-1.71),p<0.001。
- 第52周non-GC-LLDAS达标率贝利尤单抗32% vs 安慰剂21%,RR 1.50(95%CI 1.32-1.71),p<0.001。
临床怎么用
- 在解释贝利尤单抗治疗SLE的缓解和低疾病活动度数据时,可参考排除糖皮质激素成分的改良定义达标率。
- 临床评估贝利尤单抗疗效时,需注意本分析使用non-GC-DORIS和non-GC-LLDAS定义,与完整定义达标率不同。
局限性
- 本分析为事后分析,原始试验缺乏强制糖皮质激素减量方案,故采用排除GC成分的改良定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in systemic lupus erythematosus (SLE) using modified definitions that excluded the glucocorticoid (GC) component ('non-GC-DORIS' and 'non-GC-LLDAS') as the trials lacked mandated GC tapering protocols. METHODS: In this post hoc analysis, data of adults with SLE receiving belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo plus standard therapy were pooled from five clinical trials (BLISS-76 (NCT00410384), BLISS-52 (NCT00424476), North East Asia (NCT01345253), BLISS-SC (NCT01484496) and EMBRACE (NCT01632241)). Non-GC-DORIS and non-GC-LLDAS attainment rates (calculated based on SLE Disease Activity Index 2000 and Physician's Global Assessment only) with belimumab versus placebo were compared up to week 52 in the overall population and in patient subgroups of interest. RESULTS: Non-GC-DORIS and non-GC-LLDAS attainment at week 52 were significantly higher with belimumab (n=1869) versus placebo (n=1217; non-GC-DORIS: 18% vs 13%, risk ratio, RR (95% CI): 1.44 (1.20 to 1.71); p<0.001; non-GC-LLDAS: 32% vs 21%, RR (95% CI): 1.50 (1.32 to 1.71); p<0.001). Similar results were observed across most analysed patient subgroups; at week 52, differences were generally greater in the high versus low disease activity subgroups and Asian and White subgroups exhibited significantly higher attainment with belimumab versus placebo. CONCLUSION: Belimumab was associated with higher attainment of DORIS remission and LLDAS excluding the GC component versus placebo; attainment rates were approximately twofold higher than those previously reported using the full definitions.
引用
- Parodis I, Lindblom J, Levy RA, et al. Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials. RMD Open. 2026. PMID: 42399079. doi:10.1136/rmdopen-2025-006624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。